welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Stem Cell Therapy in Duchenne Muscular Dystrophy
study id #: NCT02241434
condition: Duchenne Muscular Dystrophy
The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.
intervention: Stem Cell
mechanism of action: Stem cell therapy to promote cellular regeneration
last updated: November 21, 2018
start date: January 2009
estimated completion: June 2016
phase of development: Phase 1
- Manual Muscle Testing [ Time Frame: 1 year ]
- Brooke and Vignos Scale [ Time Frame: 1 year ]
• age group of 3-25 years
• Duchenne muscular dystrophy diagnosed on the basis of clinical presentation
• presence of respiratory distress
• presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
• acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
• pregnancy or breastfeeding
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyThe proposed clinical trial study of rAA...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyStudy to characterize the single-state a...
Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced DietPlacebo-controlled, multi-centre, random...
A Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Microdystrophin Gene Transfer Study in Adolescents and Children With DMDThis is a randomized, controlled, open-l...
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of the study is to see wheth...
Ryan Benton Discusses Stem Cell Therapy for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=K94yWLJf...
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dy...Background: Edasalonexent is an orally ...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...